Aligos Therapeutics (NASDAQ:ALGS) Shares Up 7.4%

Aligos Therapeutics, Inc. (NASDAQ:ALGS) shot up 7.4% during mid-day trading on Friday . The company traded as high as $34.10 and last traded at $34.10. 1,580 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 74,336 shares. The stock had previously closed at $31.75.

A number of brokerages recently issued reports on ALGS. Piper Sandler began coverage on Aligos Therapeutics in a research report on Monday, May 17th. They issued an “overweight” rating and a $35.00 target price for the company. Zacks Investment Research raised Aligos Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 19th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $42.00 target price on shares of Aligos Therapeutics in a research report on Thursday, April 1st. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $34.50.

The business’s 50 day moving average is $25.33. The company has a market capitalization of $1.28 billion and a PE ratio of -3.08.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings data on Sunday, May 9th. The company reported ($0.74) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.90) by $0.16. The company had revenue of $0.91 million for the quarter. As a group, equities analysts expect that Aligos Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the business. New York State Common Retirement Fund purchased a new position in shares of Aligos Therapeutics during the 4th quarter worth approximately $158,000. Hillhouse Capital Advisors LTD. purchased a new position in shares of Aligos Therapeutics during the 4th quarter worth approximately $59,864,000. ETF Managers Group LLC purchased a new position in shares of Aligos Therapeutics during the 4th quarter worth approximately $482,000. Baker BROS. Advisors LP purchased a new position in shares of Aligos Therapeutics during the 4th quarter worth approximately $44,517,000. Finally, Pivotal bioVenture Partners Investment Advisor LLC purchased a new position in shares of Aligos Therapeutics during the 4th quarter worth approximately $24,237,000. 70.84% of the stock is owned by hedge funds and other institutional investors.

Aligos Therapeutics Company Profile (NASDAQ:ALGS)

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB.

Further Reading: Do You Need a Fiduciary?

Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.